XML 20 R7.htm IDEA: XBRL DOCUMENT v3.21.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Apr. 03, 2021
Mar. 28, 2020
Mar. 30, 2019
Cash Flows from Operating Activities:      
Net income $ 79,469 $ 76,526 $ 55,019
Non-cash items:      
Depreciation and amortization 84,287 110,289 109,418
Impairment of assets 21,969 50,599 21,170
Share-based compensation expense 25,516 20,454 17,188
Gain on divestiture (32,812) (8,083) 0
Deferred tax (benefit) provision (19,866) (6,958) 13,351
Unrealized loss (gain) from hedging activities 1,913 813 (24)
Provision (benefit) for losses on inventory 7,860 (2,904) 2,111
Other non-cash operating activities 151 2,043 3,798
Change in operating assets and liabilities:      
Change in accounts receivable 44,121 18,863 (38,064)
Change in inventories (38,909) (84,721) (39,322)
Change in prepaid income taxes (3,822) 1,480 (3,594)
Change in other assets and other liabilities (4,650) (2,876) 494
Change in accounts payable and accrued expenses (56,422) (17,308) 17,736
Net cash provided by operating activities 108,805 158,217 159,281
Cash Flows from Investing Activities:      
Capital expenditures (37,040) (48,758) (118,961)
Proceeds from divestiture 44,587 9,808 0
Proceeds from sale of property, plant and equipment 1,815 16,774 2,813
Acquisitions 434,804 35,000 0
Net cash used in investing activities (425,442) (57,176) (116,148)
Cash Flows from Financing Activities:      
Term loan borrowings 0 0 347,780
Repayment of term loan borrowings (21,875) (13,125) (266,853)
Net (decrease) increase in short-term loans (60,000) 45,000 15,000
Proceeds from issuance of convertible notes 500,000 0 0
Purchase of capped call related to convertible notes (47,400) 0 0
Transaction costs paid in connection with convertible notes issuance (13,457) 0 0
Proceeds from employee stock purchase plan 4,013 3,369 3,254
Proceeds from exercise of stock options 6,217 8,647 10,191
Share repurchases 0 (175,000) (160,000)
Other financing activities (46) (99) 0
Net cash provided by (used) in financing activities 367,452 (131,208) (50,628)
Effect of exchange rates on cash and cash equivalents 4,179 (1,873) (3,323)
Net Change in Cash and Cash Equivalents 54,994 (32,040) (10,818)
Cash and Cash Equivalents at Beginning of Year 137,311 169,351 180,169
Cash and Cash Equivalents at End of Year 192,305 137,311 169,351
Supplemental Disclosures of Cash Flow Information:      
Interest paid 7,824 12,545 13,116
Income taxes paid 12,487 11,507 8,205
Transfers from inventory to fixed assets for placement of Haemonetics equipment 9,287 14,479 16,345
Tenant improvement allowances excluded from capital expenditures $ 0 $ 5,660 $ 0